Singh, Simron
Ferone, Diego
Capdevila, Jaume
Chan, Jennifer Ang
de Herder, Wouter W.
Halperin, Daniel
Mailman, Josh
Hellström, Lisa
Liedman, Hanna
Svedberg, Agneta
Tiberg, Fredrik
Article History
Received: 20 June 2023
Accepted: 24 November 2023
First Online: 16 January 2024
Change Date: 2 May 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13063-024-08146-1
Declarations
:
: The trial protocol was approved by relevant ethical IRBs and IECs in the countries of treating centres. Further details of ethics approvals are available on request.Modifications to the trial protocol will be documented in a protocol amendment document and agreed upon by the Investigator and Sponsor prior to implementation. Amendments may be shared with IECs/IRBs and regulatory authorities but may be implemented prior to IEC/IRB approval to eliminate immediate hazard(s).Patients are required to provide voluntary and written informed consent on the applicable informed consent form at screening to participate in the trial, prior to any trial procedures.
: Not applicable.
: SS: Honorarium/consultancy (Camurus AB, Ipsen, Novartis-AAA); trial steering committee (Camurus AB and Novartis-AAA); institutional funding (Ipsen, Novartis-AAA). DF: Participation at advisory board/steering committees (Camurus AB, Novartis-AAA, Recordati, Sandoz); recipient of lecture fee or research grants (BMS, Camurus AB, Ipsen, Novartis-AAA, Recordati); trial steering committee (Camurus AB, Novartis-AAA). JC: Consulting or advisory role (AAA, Bayer, Eisai, Eli Lilly, Esteve, Exelixis, Ipsen, ITM, Merck Serono, Novartis, Pfizer, Roche/Genentech, Sanofi); Speakers’ Bureau (Bayer, Eisai, Eli Lilly, Esteve, Hutchison MediPharma, Ipsen, ITM, Merck Serono, Novartis, Pfizer, Sanofi); travel, accommodations, expenses (Eisai, Ipsen, Pfizer); institutional research funding (AAA, AstraZeneca, Bayer, Eisai, Ipsen, Novartis, Pfizer); trial steering committee (Camurus AB). JAC: Speaker fees (Ipsen); consulting/advisory board participation (Novartis-AAA, TerSera); trial steering committee (Camurus AB). WWdH: Speaker fees (Ipsen, Novartis-AAA); research support (Novartis-AAA); trial steering committee (Camurus AB, Novartis-AAA). DH: Consulting (Alphamedix, Amryt, Camurus AB, Crinetics, Ipsen, ITM, Novartis-AAA, TerSera); research funding (Genentech, ITM, Novartis-AAA, Tarveda, Thermo Fisher Scientific); trial steering committee (Camurus AB). JM: Consultancy/advisory board (Camurus AB, Crinetics, Ipsen, ITM AG, Novartis-AAA, Novartis, Rayze Bio); trial steering committee (Camurus AB). LH: Employee of Camurus AB. HL: Employee of Camurus AB. AS: Employee of Camurus AB (leadership role); stock and other ownership interests (Camurus AB; Cantargia AB; Genmab A/S; Zealand Pharma A/S); patients, royalties or other intellectual property (Cantargia AB). FT: Employee of Camurus AB (leadership role); stock and other ownership interests (Camurus AB); research funding (Camurus AB); patients, royalties or other intellectual property (Camurus AB)